De novo design and Rosetta-based assessment of high-affinity antibody variable regions (Fv) against the SARS-CoV-2 spike receptor binding domain (RBD)

Keyphrases

• Amino Acid Substitution 33%
• Angiotensin-converting Enzyme 2 (ACE2) 33%
• Antibody Variable Region 100%
• Antibody-based 33%
• Antigen Targeting 33%
• Binding Affinity 33%
• Binding Residues 33%
• Broad-spectrum Antibody 100%
• Computational Design 33%
• Computational Evaluation 33%
• Computational Workflow 33%
• De-novo Design 100%
• Experimental Testing 33%
• Gene Targeting 33%
• High Affinity 33%
• Human Antibody 33%
• Immune Evasion 33%
• Immunogenicity 33%
• Neutralizing Antibodies 33%
• Receptor Binding Domain 33%
• Recombination 33%
• Rosetta 100%
• SARS-CoV-2 Variants 66%
• Spike Receptor Binding Domain 33%
• Target Epitope 33%
• Virus 33%

Immunology and Microbiology

• Affinity Maturation 25%
• Amino Acid Substitution 25%
• Antibody Affinity 100%
• Antibody Design 25%
• Binding Affinity 25%
• De Novo Design 100%
• Epitope 50%
• Immune Evasion 25%
• Immunogenicity 25%
• Neutralizing Antibody 25%
• Receptor Binding 100%
• Severe Acute Respiratory Syndrome Coronavirus 2 100%
• Spike 100%
• Virus 25%